The addition of such an accomplished industry veteran as Patrick Langlois bears strong testimony to the significant opportunity ahead of Nanobiotix
PARIS (PRWEB) May 12, 2008
Since March 1, 2005, Mr. Langlois has served as a General Partner with PJL CONSEILS, a consulting firm specializing in strategy, corporate development, and M&A activities for healthcare companies. Prior to PJL, he was vice chairman of the management board and chief financial officer at Aventis (created by the merger of Rhône-Poulenc and Hoechst) from May 2002 to September 2004, and executive vice president and chief financial officer of Aventis from December 1999 to May 2002.
At Aventis, Mr. Langlois was responsible for finance, corporate development, and supervision of the company's dermatology, protein therapeutics, and animal health businesses. Earlier in his career, he was employed by Rhône-Poulenc Group from 1975 to 1999, most recently as chief financial officer and member of the executive committee. In addition to Nanobiotix, Mr. Langlois also is a board member of Shire Pharmaceuticals (UK), Scynexis (USA), and Exonhit Therapeutics (France). In addition, Mr. Langlois has served as a senior advisor to JP Morgan Healthcare since December 2006.
"The addition of such an accomplished industry veteran as Patrick Langlois bears strong testimony to the significant opportunity ahead of Nanobiotix," said Laurent Levy, Ph.D., chief executive officer of Nanobiotix. "We look forward to reaping the benefits of Patrick's considerable talent and abundant experience related to accessing the capital markets and building strong strategic partnerships."
"The Company's NanoXray platform has the potential to be a dramatic innovation in cancer therapy, based on a technology that is designed to allow destruction of cancer cells only," added Patrick Langlois. "I am very proud to be part of this important mission."
Nanobiotix is an emerging nanomedicine company combining dramatic advances in nanotechnology and molecular biology to develop nanoXray™— a technology platform
that is expected to be turned 'on' and 'off' outside the body to selectively treat a variety of cancers safely and noninvasively. Use of NanoXray is intended to resolve radiation therapy's biggest drawback: destruction of healthy tissue and its subsequent deleterious side effects when a high dose of x-ray is necessary. The core of a nanoXray nanoparticle is an inactive and inert substance—not a drug—that can subsequently be activated in order to locally (intratumor) increase the dose of x-ray, which is then expected to lead to higher efficiency. After nanoXray nanoparticles accumulate in the target tissues, a standard x-ray is applied that is intended to generate a local therapeutic effect, designed to destroy only the targeted tumor cells. This mechanism suggests total control of the intended therapeutic effect.